



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21029/S-30

SUPPLEMENT APPROVAL

Merck Sharp & Dohme, Corporation
Attention: Margarita Parente
Associate Principal Scientist, Global Regulatory Affairs
126 E. Lincoln Avenue, P.O. Box 2000
Rahway, NJ 07065-0900

Dear Ms. Parente:

Please refer to your Supplemental New Drug Application (sNDA) dated March 20, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Temodar (temozolomide), capsules: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg.

We acknowledge receipt of your amendment dated August 23, 2016, which constituted a complete response to our September 18, 2015, action letter. In that submission you state that you agree with our September 18, 2015, correspondence that the case reports regarding hepatitis B reactivation and hepatitis B reactivation-related fatalities does not warrant a change to the Warnings and Precautions section of the label because causation for the event in all cases was confounded.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed labeling text.

This submission does not modify current labeling; therefore, the package insert approved on September 18, 2015, together with the patient package insert approved on February 12, 2016, stand as the most recent version of the Temodar (temozolomide) label.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Gina Davis, Senior Regulatory Health Project Manager, at (301) 796-0704.

Sincerely,

{See appended electronic signature page}

Jeffery Summers, MD
Deputy Director for Safety
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOSEPH E GOOTENBERG on behalf of JEFFERY L SUMMERS
02/24/2017